title: Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer.
abstract: GIPC (GAIP-interacting protein, C terminus) represents a new target class for the discovery of chemotherapeutics. While many of the current generation of anticancer agents function by directly binding to intracellular kinases or cell surface receptors, the disruption of cytosolic protein-protein interactions mediated by non-enzymatic domains is an underdeveloped avenue for inhibiting cancer growth. One such example is the PDZ domain of GIPC. Previously we developed a molecular probe, the cell-permeable octapeptide CR1023 (N-myristoyl-PSQSSSEA), which diminished proliferation of pancreatic cancer cells. We have expanded upon that discovery using a chemical modification approach and here report a series of cell-permeable, side chain-modified lipopeptides that target the GIPC PDZ domain in vitro and in vivo. These peptides exhibit significant activity against pancreatic and breast cancers, both in cellular and animal models. CR1166 (N-myristoyl-PSQSK(εN-4-bromobenzoyl)SK(εN-4-bromobenzoyl)A), bearing two halogenated aromatic units on alternate side chains, was found to be the most active compound, with pronounced down-regulation of EGFR/1GF-1R expression. We hypothesize that these organic acid-modified residues extend the productive reach of the peptide beyond the canonical binding pocket, which defines the limit of accessibility for the native proteinogenic sequences that the PDZ domain has evolved to recognize. Cell permeability is achieved with N-terminal lipidation using myristate, rather than a larger CPP (cell-penetrating peptide) sequence. This, in conjunction with optimization of targeting through side chain modification, has yielded an approach that will allow the discovery and development of next-generation cellular probes for GIPC PDZ as well as for other PDZ domains.
authors.affiliation: Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States.
authors.forename: Chitta Ranjan
authors.initials: CR
authors.lastname: Patra
authors.forename: Chamila N
authors.initials: CN
authors.lastname: Rupasinghe
authors.forename: Shamit K
authors.initials: SK
authors.lastname: Dutta
authors.forename: Santanu
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: Enfeng
authors.initials: E
authors.lastname: Wang
authors.forename: Mark R
authors.initials: MR
authors.lastname: Spaller
authors.forename: Debabrata
authors.initials: D
authors.lastname: Mukhopadhyay
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000627:therapeutic use; D054731:PDZ Domains / Q000187:drug effects*; D013329:Structure-Activity Relationship
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C492009:GIPC1 protein, human; D009842:Oligopeptides